✦ LIBER ✦

Induction Therapy for Patients with Multiple Sclerosis: Why? When? How?

✍ Scribed by Edan, Gilles; Page, Emmanuelle

Book ID: 120444254
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2013
Tongue: English
Weight: 235 KB
Volume: 27
Category: Article
ISSN: 1172-7047
DOI: 10.1007/s40263-013-0065-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Why, when and how to initiate insulin th

Why, when and how to initiate insulin therapy in patients with type 2 diabetes

✍ J. Tibaldi; R. E. Rakel 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 589 KB

Testosterone therapy in patients with er

Testosterone therapy in patients with erectile dysfunction: When to start? When to give alone? When to combine? And for how long?

✍ Aksam A. Yassin; Farid Saad; Svetlana Kalenchenko 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 190 KB

Treatment options for patients with mult

Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon- β therapy

✍ Freedman, M. S. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 565 KB

Alemtuzumab for patients with relapsing

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

✍ Alasdair J Coles; Cary L Twyman; Douglas L Arnold; Jeffrey A Cohen; Christian Co 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 326 KB

Expert opinion: Guidelines for the use o

Expert opinion: Guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies

✍ R. Gold; A. Jawad; D.H. Miller; D.C. Henderson; A. Fassas; W. Fierz; H.P. Hartun 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 100 KB

Bortezomib, thalidomide, and dexamethaso

Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma : A retrospective study

✍ Jonathan L. Kaufman; Ajay Nooka; Mark Vrana; Charise Gleason; L. Thompson Heffne 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB

## Abstract ## BACKGROUND: This single‐center retrospective study determined the efficacy of bortezomib, thalidomide, and dexamethasone (BTD) as induction for patients with multiple myeloma (MM) who were eligible for autologous stem cell transplantation (ASCT). ## METHODS: Patients with symptoma